Oct 2026· Reviews in cardiovascular medicine· Vol 27· 0 citations· 23 references
Medicine
TL;DR
For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
Abstract
Background: Although drug-coated balloons (DCBs) outperform drug-eluting stents (DESs) in the treatment of de novo small-vessel coronary lesions, no comparable studies are available for de novo large-vessel coronary lesions. Methods: This retrospective study examined 960 patients with de novo large-vessel coronary lesions (reference vessel diameter ≥3.0 mm) who underwent paclitaxel DCB angioplasty or DES implantation at Beijing Anzhen Hospital. The study endpoints included all-cause death, myocardial infarction (MI), stroke, and target vessel revascularization (TVR). Kaplan–Meier (KM) curves and Cox regression analysis were used to investigate the clinical outcomes of patients in the DCB and DES groups. Results: The overall incidence rates of major adverse cardiac and cerebrovascular events (MACCEs), all-cause death, MI, stroke, and TVR were 9.27% (89/960), 1.5% (14 patients), 0.9% (9 patients), 0.6% (6 patients), and 6.8% (65 patients), respectively. No significant differences were observed between the DCB and DES groups in MACCEs (13.2% vs. 5.6%; p = 0.511), all-cause death (1.9% vs. 1.0%; p = 0.763), MI (0.6% vs. 1.2%; p = 0.239), or stroke (0.6% vs. 0.6%; p = 0.361). However, the TVR rate was significantly higher in the DCB group than in the DES group (10.1% vs. 3.6%; p = 0.028), and this difference persisted after multivariate adjustment. Conclusions: For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
Objective This meta-analysis aimed to compare the efficacy and safety of drug-coated balloons (DCB) vs. drug-eluting stents (DES) in patients with de novo small coronary artery disease. Methods We systematically searched PubMed, Embase, Cochrane Library, and Web of Science from inception to March 18, 2024, for randomiz...
Yan-Jie Gao, Ming Lian· Frontiers in Cardiovascular...· 0 citations
Drug-coated balloon (DCB) angioplasty has emerged as a promising alternative to drug eluting stent (DES) implantation, particularly in small-vessel coronary disease (defined as target vessels with a reference diameter ≤2.75 mm). Nevertheless, multicenter real-world data focusing exclusively on de novo lesions remain...
N. Tsiamis, A. Papanikolaou, F. Toulgaridis et al.· European Heart Journal· 0 citations
AIM
Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...
Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al.· American Journal of Cardiolo...· 0 citations
The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy, which was comparable to a DES only strategy.
H. Khan, M. Egred, M. Alkhalil et al.· European Heart Journal· 0 citations
Drug-coated balloon (DCB) has emerged as potential alternative to drug-eluting stents (DES) in specific lesion subsets for de novo coronary lesions. However, evidence supporting DCB in severely calcified lesions remains limited. Quantitative flow ratio (QFR) is a noninvasive quantitative tool for evaluating post-...
Q. Qin, L. Chen, Ren-De Xu et al.· European Heart Journal· 0 citations
Drug-coated balloons (DCB) are established therapy for coronary in-stent restenosis and are increasingly used in small-vessel disease, where they showed non-inferiority to DES in randomized trials such as BASKET-SMALL 2. Current ESC and international consensus documents primarily frame DCB as a strategy for ISR a...
L. Hamann, D. Faria, J. Pereira et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.